Targeting HER3 with miR-450b-3p suppresses breast cancer cells proliferation

Reference

• Ullrich A, Coussens L, Hayflick JS, Dull TJ, Gray A, Tam AW, Lee J, Yarden Y, Libermann TA, Schlessinger J, et al. Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells. Nature 1984; 309:418 - 25; http://dx.doi.org/10.1038/309418a0; PMID: 6328312
   PubMed Web of Science ®Google Scholar
• Ullrich A, Schlessinger J. Signal transduction by receptors with tyrosine kinase activity. Cell 1990; 61:203 - 12; http://dx.doi.org/10.1016/0092-8674(90)90801-K; PMID: 2158859
   PubMed Web of Science ®Google Scholar
• Shiraishi M, Noguchi M, Shimosato Y, Sekiya T. Amplification of protooncogenes in surgical specimens of human lung carcinomas. Cancer Res 1989; 49:6474 - 9; PMID: 2573414
   PubMed Web of Science ®Google Scholar
• Gerosa MA, Talarico D, Fognani C, Raimondi E, Colombatti M, Tridente G, De Carli L, Della Valle G. Overexpression of N-ras oncogene and epidermal growth factor receptor gene in human glioblastomas. J Natl Cancer Inst 1989; 81:63 - 7; http://dx.doi.org/10.1093/jnci/81.1.63; PMID: 2908920
   PubMed Web of Science ®Google Scholar
• Cowley GP, Smith JA, Gusterson BA. Increased EGF receptors on human squamous carcinoma cell lines. Br J Cancer 1986; 53:223 - 9; http://dx.doi.org/10.1038/bjc.1986.39; PMID: 2420349
   PubMed Web of Science ®Google Scholar
• Rao VH, Kandel A, Lynch D, Pena Z, Marwaha N, Deng C, Watson P, Hansen LA. A positive feedback loop between HER2 and ADAM12 in human head and neck cancer cells increases migration and invasion. Oncogene 2012; 31:2888 - 98; http://dx.doi.org/10.1038/onc.2011.460; PMID: 21986939
   PubMed Web of Science ®Google Scholar
• Berger MB, Mendrola JM, Lemmon MA. ErbB3/HER3 does not homodimerize upon neuregulin binding at the cell surface. FEBS Lett 2004; 569:332 - 6; http://dx.doi.org/10.1016/j.febslet.2004.06.014; PMID: 15225657
   PubMed Web of Science ®Google Scholar
• Vaught DB, Stanford JC, Young C, Hicks DJ, Wheeler F, Rinehart C, Sánchez V, Koland J, Muller WJ, Arteaga CL, et al. HER3 is required for HER2-induced preneoplastic changes to the breast epithelium and tumor formation. Cancer Res 2012; 72:2672 - 82; http://dx.doi.org/10.1158/0008-5472.CAN-11-3594; PMID: 22461506
   PubMed Web of Science ®Google Scholar
• Alimandi M, Romano A, Curia MC, Muraro R, Fedi P, Aaronson SA, Di Fiore PP, Kraus MH. Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas. Oncogene 1995; 10:1813 - 21; PMID: 7538656
   PubMed Web of Science ®Google Scholar
• Soltoff SP, Carraway KL 3rd, Prigent SA, Gullick WG, Cantley LC. ErbB3 is involved in activation of phosphatidylinositol 3-kinase by epidermal growth factor. Mol Cell Biol 1994; 14:3550 - 8; PMID: 7515147
   PubMed Web of Science ®Google Scholar
• Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen J, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007; 316:1039 - 43; http://dx.doi.org/10.1126/science.1141478; PMID: 17463250
   PubMed Web of Science ®Google Scholar
• Prigent SA, Gullick WJ. Identification of c-erbB-3 binding sites for phosphatidylinositol 3′-kinase and SHC using an EGF receptor/c-erbB-3 chimera. EMBO J 1994; 13:2831 - 41; PMID: 8026468
   PubMed Web of Science ®Google Scholar
• Bezler M, Hengstler JG, Ullrich A. Inhibition of doxorubicin-induced HER3-PI3K-AKT signalling enhances apoptosis of ovarian cancer cells. Mol Oncol 2012; 6:516 - 29; http://dx.doi.org/10.1016/j.molonc.2012.07.001; PMID: 22841590
   PubMed Web of Science ®Google Scholar
• Chakrabarty A, Sánchez V, Kuba MG, Rinehart C, Arteaga CL. Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors. Proc Natl Acad Sci U S A 2012; 109:2718 - 23; http://dx.doi.org/10.1073/pnas.1018001108; PMID: 21368164
   PubMed Web of Science ®Google Scholar
• Scott GK, Goga A, Bhaumik D, Berger CE, Sullivan CS, Benz CC. Coordinate suppression of ERBB2 and ERBB3 by enforced expression of micro-RNA miR-125a or miR-125b. J Biol Chem 2007; 282:1479 - 86; http://dx.doi.org/10.1074/jbc.M609383200; PMID: 17110380
   PubMed Web of Science ®Google Scholar
• Amin DN, Sergina N, Lim L, Goga A, Moasser MM. HER3 signalling is regulated through a multitude of redundant mechanisms in HER2-driven tumour cells. Biochem J 2012; 447:417 - 25; http://dx.doi.org/10.1042/BJ20120724; PMID: 22853430
   PubMed Web of Science ®Google Scholar
• Baek D, Villén J, Shin C, Camargo FD, Gygi SP, Bartel DP. The impact of microRNAs on protein output. Nature 2008; 455:64 - 71; http://dx.doi.org/10.1038/nature07242; PMID: 18668037
   PubMed Web of Science ®Google Scholar
• He L, Hannon GJ. MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet 2004; 5:522 - 31; http://dx.doi.org/10.1038/nrg1379; PMID: 15211354
   PubMed Web of Science ®Google Scholar
• Lee-Hoeflich ST, Crocker L, Yao E, Pham T, Munroe X, Hoeflich KP, Sliwkowski MX, Stern HM. A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy. Cancer Res 2008; 68:5878 - 87; http://dx.doi.org/10.1158/0008-5472.CAN-08-0380; PMID: 18632642
   PubMed Web of Science ®Google Scholar
• Epis MR, Giles KM, Barker A, Kendrick TS, Leedman PJ. miR-331-3p regulates ERBB-2 expression and androgen receptor signaling in prostate cancer. J Biol Chem 2009; 284:24696 - 704; http://dx.doi.org/10.1074/jbc.M109.030098; PMID: 19584056
   PubMed Web of Science ®Google Scholar
• Iorio MV, Casalini P, Piovan C, Di Leva G, Merlo A, Triulzi T, Ménard S, Croce CM, Tagliabue E. microRNA-205 regulates HER3 in human breast cancer. Cancer Res 2009; 69:2195 - 200; http://dx.doi.org/10.1158/0008-5472.CAN-08-2920; PMID: 19276373
   PubMed Web of Science ®Google Scholar
• Delić D, Dkhil M, Al-Quraishy S, Wunderlich F. Hepatic miRNA expression reprogrammed by Plasmodium chabaudi malaria. Parasitol Res 2011; 108:1111 - 21; http://dx.doi.org/10.1007/s00436-010-2152-z; PMID: 21085987
   PubMed Web of Science ®Google Scholar
• Svoboda M, Sana J, Fabian P, Kocakova I, Gombosova J, Nekvindova J, Radova L, Vyzula R, Slaby O. MicroRNA expression profile associated with response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer patients. Radiat Oncol 2012; 7:195; http://dx.doi.org/10.1186/1748-717X-7-195; PMID: 23167930
   PubMed Web of Science ®Google Scholar
• Volinia S, Galasso M, Sana ME, Wise TF, Palatini J, Huebner K, Croce CM. Breast cancer signatures for invasiveness and prognosis defined by deep sequencing of microRNA. Proc Natl Acad Sci U S A 2012; 109:3024 - 9; http://dx.doi.org/10.1073/pnas.1200010109; PMID: 22315424
   PubMed Web of Science ®Google Scholar
• Ferracin M, Querzoli P, Calin GA, Negrini M. MicroRNAs: toward the clinic for breast cancer patients. Semin Oncol 2011; 38:764 - 75; http://dx.doi.org/10.1053/j.seminoncol.2011.08.005; PMID: 22082762
   PubMed Web of Science ®Google Scholar
• Gaur A, Jewell DA, Liang Y, Ridzon D, Moore JH, Chen C, Ambros VR, Israel MA. Characterization of microRNA expression levels and their biological correlates in human cancer cell lines. Cancer Res 2007; 67:2456 - 68; http://dx.doi.org/10.1158/0008-5472.CAN-06-2698; PMID: 17363563
   PubMed Web of Science ®Google Scholar
• Garrett JT, Olivares MG, Rinehart C, Granja-Ingram ND, Sánchez V, Chakrabarty A, Dave B, Cook RS, Pao W, McKinely E, et al. Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase. Proc Natl Acad Sci U S A 2011; 108:5021 - 6; http://dx.doi.org/10.1073/pnas.1016140108; PMID: 21385943
   PubMed Web of Science ®Google Scholar
• Ocana A, Vera-Badillo F, Seruga B, Templeton A, Pandiella A, Amir E. HER3 overexpression and survival in solid tumors: a meta-analysis. J Natl Cancer Inst 2013; 105:266 - 73; http://dx.doi.org/10.1093/jnci/djs501; PMID: 23221996
   PubMed Web of Science ®Google Scholar
• Takikita M, Xie R, Chung JY, Cho H, Ylaya K, Hong SM, Moskaluk CA, Hewitt SM. Membranous expression of Her3 is associated with a decreased survival in head and neck squamous cell carcinoma. J Transl Med 2011; 9:126; http://dx.doi.org/10.1186/1479-5876-9-126; PMID: 21801427
   PubMed Web of Science ®Google Scholar
• Trocmé E, Mougiakakos D, Johansson CC, All-Eriksson C, Economou MA, Larsson O, Seregard S, Kiessling R, Lin Y. Nuclear HER3 is associated with favorable overall survival in uveal melanoma. Int J Cancer 2012; 130:1120 - 7; http://dx.doi.org/10.1002/ijc.26118; PMID: 21484789
   PubMed Web of Science ®Google Scholar
• Abd El-Rehim DM, Pinder SE, Paish CE, Bell JA, Rampaul RS, Blamey RW, Robertson JF, Nicholson RI, Ellis IO. Expression and co-expression of the members of the epidermal growth factor receptor (EGFR) family in invasive breast carcinoma. Br J Cancer 2004; 91:1532 - 42; http://dx.doi.org/10.1038/sj.bjc.6602184; PMID: 15480434
   PubMed Web of Science ®Google Scholar
• Suo Z, Risberg B, Kalsson MG, Willman K, Tierens A, Skovlund E, Nesland JM. EGFR family expression in breast carcinomas. c-erbB-2 and c-erbB-4 receptors have different effects on survival. J Pathol 2002; 196:17 - 25; http://dx.doi.org/10.1002/path.1003; PMID: 11748637
   PubMed Web of Science ®Google Scholar
• Renart J, Reiser J, Stark GR. Transfer of proteins from gels to diazobenzyloxymethyl-paper and detection with antisera: a method for studying antibody specificity and antigen structure. Proc Natl Acad Sci U S A 1979; 76:3116 - 20; http://dx.doi.org/10.1073/pnas.76.7.3116; PMID: 91164
   PubMed Web of Science ®Google Scholar
• Franken NA, Rodermond HM, Stap J, Haveman J, van Bree C. Clonogenic assay of cells in vitro. Nat Protoc 2006; 1:2315 - 9; http://dx.doi.org/10.1038/nprot.2006.339; PMID: 17406473
   PubMed Web of Science ®Google Scholar
• Liu AW, Cai J, Zhao XL, Jiang TH, He TF, Fu HQ, Zhu MH, Zhang SH. ShRNA-targeted MAP4K4 inhibits hepatocellular carcinoma growth. Clin Cancer Res 2011; 17:710 - 20; http://dx.doi.org/10.1158/1078-0432.CCR-10-0331; PMID: 21196414
   PubMed Web of Science ®Google Scholar